RECURSION PHARMACEUTICALS

Company snapshot

Acurx Pharmaceuticals is a publicly held, clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for RECURSION PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Inhibrx Biosciences

  TA overlap score 22

Recent activity

Latest pipeline, patent, and corporate events for RECURSION PHARMACEUTICALS.

1. Jun 5, 2026 Clinical update

   REC-4881 — Phase 2

2. Jun 5, 2026 Clinical update

   EXS73565 — Phase 1

3. May 23, 2026 Clinical update

   REC-2282 — Phase 3

4. May 23, 2026 Clinical update

   GTAEXS617 — Phase 2

5. May 23, 2026 Clinical update

   REC-1245 — Phase 2

View all clinical trial activity →

• What is RECURSION PHARMACEUTICALS?

  RECURSION PHARMACEUTICALS is a biotech organization headquartered in Staten Island, USA. It trades on NYSE under ticker RXRX. Primary therapeutic focus areas include Relapsed or Refractory B-cell Malignancies, Solid Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC), Unresectab

• Is RECURSION PHARMACEUTICALS publicly traded?

  Yes. RECURSION PHARMACEUTICALS is listed with ticker RXRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does RECURSION PHARMACEUTICALS develop or market?

  We link 2 drug profile(s) where RECURSION PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/recursion-pharmaceuticals-inc#company-drugs.

• What are the latest developments for RECURSION PHARMACEUTICALS?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does RECURSION PHARMACEUTICALS focus on?

  RECURSION PHARMACEUTICALS focuses on Relapsed or Refractory B-cell Malignancies, Solid Tumor, Head and Neck Squamous Cell Carcinoma (HNSCC) based on our analysis of their pipeline programs and drug development activities.